spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  fluorouracil 

 HSMN NewsFeed - 18 Sep 2024
Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of 420mg Strength of HERCESSI(TM) (trastuzumab-strf), a biosimilar to Herceptin(R) (trastuzumab), for the Treatment of Several Forms of HER2-Overexpressing Cancer
Biopharmaceuticals Generics Oncology FDA
 HSMN NewsFeed - 9 Jun 2023
Astellas Submits New Drug Application for Zolbetuximab in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Jul 2021
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 May 2021
FDA Grants Bold Therapeutics' BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Mar 2020
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Sep 2019
Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Feb 2019
BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Oct 2018
OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Submission of Investigational New Drug Application to Evaluate Tedopi(R) in Combination with Nivolumab in Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Aug 2018
Tocagen's Toca 5 Pivotal Phase 3 Clinical Trial in Patients with Recurrent Brain Cancer Continues Without Modification at Planned First Interim Analysis
Biopharmaceuticals Neurology Oncology
 HSMN NewsFeed - 19 Apr 2018
Tocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 & Toca FC in the Greater China Region
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 10 Nov 2017
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Sep 2017
Oncolytics Biotech(R) Announces the Presentation of REOLYSIN(R) Clinical Data at ESMO 2017 Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Aug 2017
ARMO BioSciences Raises $67 Million in a Series C-1 Financing
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 31 May 2017
Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA(R) (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2017
New ASTRO Guideline Establishes Standard of Care for Curative Treatment of Oropharyngeal Cancer with Radiation Therapy
Devices Oncology
 HSMN NewsFeed - 9 Jan 2017
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 18 Oct 2016
Shire Granted EU Marketing Authorization of Onivyde(R), in Combination With 5-Fluorouracil (5-FU) and Leucovorin (LV),for the Treatment of Metastatic Adenocarcinoma of the Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Jul 2016
ONIVYDE(R) Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Following Gemcitabine Based Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Mar 2016
Merrimack Announces Inclusion of ONIVYDE(R) (irinotecan liposome injection) as a Category 1 Treatment Option in the 2016 NCCN Guidelines for Pancreatic Adenocarcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Feb 2016
Cipher Pharmaceuticals Inc. announces Canadian launch of Actikerall(TM)
Biopharmaceuticals Dermatology Product Launch
 HSMN NewsFeed - 22 Oct 2015
Merrimack Announces U.S. FDA Approval of ONIVYDE(TM) (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Mar 2015
Sirtex Reports Preliminary SIRFLOX Study Results
Devices Drug Delivery Oncology
 HSMN NewsFeed - 14 Aug 2014
FDA Approves Genentech’s Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 May 2014
Merrimack Pharmaceuticals Announces MM-398 Achieves Primary Endpoint of Overall Survival in Phase 3 Trial in Post-Gemcitabine Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Feb 2013
ZALTRAP(R) (ziv-aflibercept) Approved in the EU for Patients with Previously Treated Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Jan 2013
Spectrum Pharmaceuticals Announces Promotion of Joseph Turgeon to Senior Vice President and Chief Commercial Officer as Company Builds on Recent Commercial Reorganization to Advance Growth and Market Penetration over the Next Five Years
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Oct 2012
Sagent Pharmaceuticals Announces the Launch of Leucovorin Calcium for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Aug 2012
Spectrum Pharmaceuticals Launches a Broad-based FUSILEV(R) Marketing Campaign; Increases Sales Force Footprint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Mar 2012
Largest Comparative Study of Radioembolisation Shows SIR-Spheres Microspheres Significantly Improves Survival for Cancer Patients with Inoperable Liver Tumours
Devices Oncology
 HSMN NewsFeed - 27 Jan 2012
Saladax Biomedical, Inc. Announces the Resignation of Edward L. Erickson as President and Chief Executive Officer
Diagnostics Personalized Medicine Personnel
 HSMN NewsFeed - 12 Oct 2011
Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Sep 2011
Bristol-Myers Squibb and Saladax Biomedical Expand Collaboration for Diagnostic Assays for Alzheimer’s Disease
Diagnostics Neurology
 HSMN NewsFeed - 15 Jul 2011
Pertuzumab Combined With Herceptin and Chemotherapy Significantly Extended the Time People With HER2-Positive Metastatic Breast Cancer Lived Without Their Disease Getting Worse
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Jun 2011
ZALTRAP (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 May 2011
Saladax Biomedical, Inc. Announces European Commercialization Team
Diagnostics Personalized Medicine Personnel
 HSMN NewsFeed - 18 Mar 2011
Amgen Statement on CHMP Opinion on Vectibix(R) (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Mar 2011
Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Feb 2011
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Dec 2010
Pertuzumab and Herceptin Plus Chemotherapy Significantly Improved the Rate of Complete Tumor Disappearance in Study of Women With Newly Diagnosed, Early-Stage HER2-Positive Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jun 2010
ADVENTRX Grants Exclusive Worldwide Rights to CoFactor Know-How and Data
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 Apr 2010
Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Apr 2010
Genta's Tesetaxel Granted Fast Track Designation by FDA for Advanced Gastric Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Apr 2010
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Aug 2009
Hospira Launches Generic Oxaliplatin Injection
Biopharmaceuticals Generics Oncology FDA
 HSMN NewsFeed - 1 Jun 2009
Randomized Controlled Trial of Radioactive Resin Microspheres Demonstrates Significant Delay in Progression of Disease in Patients with Colorectal Cancer Liver Metastases who have Exhausted Chemotherapy
Biopharmaceuticals Oncology Gastroenterology
 HSMN NewsFeed - 22 Apr 2009
Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Feb 2009
Genta Submits Randomized Study of Tesetaxel in Patients with Advanced Gastric Cancer to FDA for Special Protocol Assessment
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Jan 2009
FDA Provides Clear Path to NDA Submission for Pro-Pharmaceuticals’ DAVANAT(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Jan 2009
New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Oct 2008
Spectrum Pharmaceuticals Files Supplemental New Drug Application with FDA for FUSILEV(TM) in Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2008
Genentech Announces Phase III Study of Avastin Plus Chemotherapy in Adjuvant Colon Cancer Will Continue
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Sep 2008
VioQuest Pharmaceuticals Receives 510(k) Response from FDA for Xyfid(TM)
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 3 Sep 2008
ImClone Submits Supplemental Biologics License Application for ERBITUX(R) in First-Line Head and Neck Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Aug 2008
Spectrum Pharmaceuticals Launches FUSILEV(TM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Jun 2008
Spectrum Pharmaceuticals Announces FUSILEV(TM) as Tradename for Levoleucovorin for Injection
Biopharmaceuticals
 HSMN NewsFeed - 5 Jun 2008
New Drug Application Filing for Levoleucovorin Tablets Completed by Spectrum Pharmaceuticals, Inc.
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 May 2008
Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2008
Valeant Pharmaceuticals Announces FDA Has Initiated Reconsideration of Generic Efudex(R) Approval
Biopharmaceuticals Generics Dermatology FDA
 HSMN NewsFeed - 17 Apr 2008
Angiotech's novel 5-FU Central Venous Catheter receives FDA 510(k) clearance
Biopharmaceuticals Devices FDA
 HSMN NewsFeed - 16 Apr 2008
Graceway Pharmaceuticals Reports Study in British Journal of Dermatology: Patients Treated with ALDARA Experienced Higher Levels of Histological and Sustained Clearance for Actinic Keratosis (AK) than Patients in two Other Common AK Treatments
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 20 Mar 2008
Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Mar 2008
960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter
Devices Biopharmaceuticals
 HSMN NewsFeed - 7 Mar 2008
FDA Approves New Drug Application (NDA) for LEVOleucovorin, Spectrum's First Proprietary Oncology Drug
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Mar 2008
Pro-Pharmaceuticals DAVANAT(R) Extends Median Survival 6.7 Months for End-Stage Colorectal Cancer Patients After All Other Treatments Failed
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Feb 2008
APP Pharmaceuticals Receives Final Approval for Irinotecan Hydrochloride Injection
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 27 Feb 2008
Hospira Launches Generic Irinotecan Injection
Biopharmaceuticals Oncology Generics
 HSMN NewsFeed - 11 Feb 2008
New Data Shows DAVANAT(R) Extends Survival of End-Stage Colorectal Cancer Patients More Than 6 Months
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jan 2008
Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jan 2008
Xeloda(R) Combination Therapy in Esophagogastric Cancer Highlighted in New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Dec 2007
Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
Devices
 HSMN NewsFeed - 17 Dec 2007
Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Dec 2007
Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Oct 2007
Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Oct 2007
Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
Devices FDA
 HSMN NewsFeed - 5 Oct 2007
APP Receives Tentative FDA Approval for Irinotecan Hydrochloride Injection, 20 mg/mL Packaged in 2 mL and 5 mL Single-Use Vials
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 1 Oct 2007
Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Sep 2007
Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Sep 2007
Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Aug 2007
ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Jul 2007
Myriad Genetics Launches New Molecular Diagnostic Test
Diagnostics Oncology
 HSMN NewsFeed - 10 Jul 2007
Angiotech completes enrolment in its Central Venous Catheter (CVC) Pivotal Study
Devices
 HSMN NewsFeed - 28 Jun 2007
Pfizer Initiates Phase III Trial to Study Sunitinib Malate in Patients with Metastatic Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jun 2007
Taxotere(R) (docetaxel) Granted FDA Priority Review for Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck Prior to Chemoradiotherapy and Surgery
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 18 Jun 2007
Health Canada approves new chemotherapy treatment for patients with metastatic colorectal cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Jun 2007
The Eloxatin(R)-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
S-1, a Novel Oral Fluoropyrimidine, When Combined With Cisplatin, Demonstrates Significant Improvement in Overall Survival of Advanced Gastric Cancer Patients Over S-1 Alone
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Xeloda(R) Plus Avastin(R) Combination Delays Disease Progression in Women with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Biweekly Xeloda(R) Dosing Regimen is Well Tolerated in Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2007
Pro-Pharmaceuticals Issues Corporate Update
Biopharmaceuticals
 HSMN NewsFeed - 12 Apr 2007
Pro-Pharmaceuticals Plans to Submit a New Drug Application for DAVANAT(R), as a Functional Excipient, with 5-FU to Treat Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Apr 2007
Pro-Pharmaceuticals Receives Letter from the FDA for New Drug Application for DAVANAT(R)/ 5-FU
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Apr 2007
Pro-Pharmaceuticals Announces Tampa General Hospital Dosing Patients with DAVANAT(R)/5-FU in Phase II, First Line, Advanced Biliary Cancer Clinical Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2007
Survival Data Available From ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Mar 2007
Roche Submits Application to the FDA for use of XELOX (Xeloda(R) plus oxaliplatin) With or Without Avastin(R) for the Treatment of Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Feb 2007
Pro-Pharmaceuticals Submits Orphan Drug Status Application to European Medicines Agency Co-administration of DAVANAT(R) with 5-FU to Treat Cholangiocarcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Feb 2007
Pro-Pharmaceuticals Meeting Scheduled with the FDA
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Feb 2007
Pro-Pharmaceuticals' Begins Process of New Drug Application Submission with the FDA for Co-administration of DAVANAT(R) with 5-FU in Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jan 2007
NCCN Updates Colon Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Jan 2007
DUSA Pharmaceuticals, Inc.: International Guidelines Recommend Photodynamic Therapy as First-Line Treatment for Actinic Keratoses
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 22 Jan 2007
Results Show XELOX (Xeloda(R) plus oxaliplatin) Provides Equivalent Overall Patient Survival Compared to FOLFOX in Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Dec 2006
ADVENTRX Initiates CoFactor Phase II Clinical Trial in Refractory Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Dec 2006
Anthracyclines May Not Be for Everyone: Report From the 29th Annual San Antonio Breast Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Dec 2006
Xeloda(R) Plus Avastin(R) Combination May Produce Clinical Benefit in Patients with Advanced Breast Cancer
Biopharmaceuticaals Oncology
 HSMN NewsFeed - 14 Dec 2006
New Data On Pfizer's Aromasin and Ellence to Be Presented at San Antonio Breast Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Abraxis BioScience to Present Data from Six Studies at San Antonio Breast Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Xeloda(R) Combination Meets Primary Endpoint in International Phase III Advanced Colorectal Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Oct 2006
Taxotere(R) Receives U.S. FDA Approval for the Treatment of Patients With Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Oct 2006
FDA Approves Avastin(R) in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Oct 2006
XELOX (Xeloda(R) + oxaliplatin) Shown to be as Effective as Current Standard in the Treatment of Advanced Colorectal Cancer for Progression-Free Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Sep 2006
Poniard Pharmaceuticals Expands Picoplatin Agreement to Include Exclusive Worldwide Rights and Improved Financial Terms and Conditions
Biopharmaceuticals Licensing
 HSMN NewsFeed - 29 Jun 2006
ADVENTRX Presents Encouraging New Supplemental Results for the CoFactor Phase II Metastatic Colorectal Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jun 2006
ADVENTRX Presents CoFactor Pharmacokinetics Data
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2006
ADVENTRX Initiates CoFactor Phase III Clinical Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jun 2006
Data Safety Monitoring Board Recommends Continuation of ADVENTRX Phase IIb Clinical Trial for CoFactor
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 May 2006
Recruitment Planned to Resume in AVANT International Phase III Trial in Adjuvant Colon Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2006
ADVENTRX Receives FDA Clearance Under a Special Protocol Assessment to Initiate CoFactor Phase III Clinical Trial
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 122

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 122 additional stories matching:
fluorouracil
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!